CRO Accelovance launches oncology-focused initiative

10-Apr-2017 - Last updated on 11-Apr-2017 at 14:11 GMT

Accelovance was established in 2005. (Image: iStock/BrianAJackson)

Accelovance has launched a global initiative dedicated to advancing early phase oncology therapies – an “underserved focus of CROs,” it says.

The Rockville, MD-headquartered contract research organization (CRO) focuses on oncology, vaccine/immunology, and general medicine clinical research.

Its new initiative HERO — “Helping Early Research in Oncology”— focuses entirely on early phase oncology research.

“Our HERO Initiative encapsulates our vision of purpose and collaboration to improve early phase oncology research, which has generally been an underserved segment/focus of CROs,” John W. Colby III, AVP, Proposals and Marketing at Accelovance told Outsourcing-Pharma.com.

The company has been working on the HERO initiative for nearly two years and its build out has consisted of several elements, Colby explained, including developing site relationships with early phase and phase I oncology centers of excellence.

The CRO has also invested in staff with early phase oncology expertise.

“Finally we have purposefully selected products for inclusion in our HERO oriented clinical technology suite,” said Colby. “This technology suite supports our teams and sponsors with robust data analytics, data mining and monitoring as well as providing our sponsors with standard and customizable reports to monitor the performance of the study overall.”

Colby said the aim is the challenge “the status quo of building everything from scratch and having elongated start-ups.”

“The goal is to enable our sponsors to achieve faster go/no decisions with their early phase candidates and expedite their ability to reach critical milestones in their development and financial plans of their organizations,” he added.